This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

For the management of serious bacterial infections in critically ill patients​​​​​​​

Pfizer has a strong portfolio in licensed products for the treatment of pneumonia, including ZAVICEFTA® (ceftazidime and avibactam) and ZINFORO® (ceftaroline fosamil)*†1,2

Zavicefta® is indicated for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
Zinforo® is indicated for the treatment of community-acquired pneumonia (CAP) in neonates, infants, children, adolescents and adults2

Community Acquired Pneumonia (CAP)

When there’s no time to wait, evidence supports the use of Zinforo® in your CAP patients:

  • Fifth-generation cephalosporin with coverage against key causative pathogens in post-influenza CAP3,4
  • High clinical cure rates and rapid-response at Day 4 in CAP, including in complex patients with comorbidities5,6
  • Relatively low protein binding (20%) and using data comparing protein binding with rate of penetration to the site of infection, would be predicted to have a rapid penetration rate7,8
  • Established safety and tolerability profile consistent with other cephalosporins5
  • Simple dosing for the majority of patients, with a flexible 5-60 minute infusion time and no dosage adjustment required for most elderly patients and those with mild renal impairment or hepatic impairmentβ2

Access the details of clinical trial output, and practical use of Zinforo


Hospital-Acquired Pneumonia (HAP)/Ventilator-Acquired Pneumonia (VAP)

The efficacy and safety profile of Zavicefta® make it a much-needed option for physicians faced with the challenge of treating hospitalised patients with HAP/VAP caused by suspected or confirmed resistant, aerobic Gram-negative bacteria, where the consequences of antibiotic failure can be devastating1,9,11,12

  • Zavicefta is as effective as a carbapenem in hospitalised patients with aerobic Gram-negative HAP, including VAP9,10
  • Zavicefta has an established safety and tolerability profile consistent with both cephalosporins and carbapenems9,13-15

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

Access case studies and videos

**Zavicefta is indicated for treatment of complicated urinary tract infections, including pyelonephritis; complicated intra-abdominal infections; and hospital-acquired pneumonia, including ventilator-associated pneumonia infections in adults and paediatric patients aged 3 months and older. 
Zavicefta is also indicated for the treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.1
†Zinforo® is indicated for the treatment of patients with complicated skin and soft tissue infections and community-acquired pneumonia.2
‡Applies only for standard dose regimens in adults and children from 2 months of age, including patients with renal impairment. For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis). Infusion times of <60 minutes are based on PK/PD analyses only.1
βDosage adjustment required for patients with moderate or severe renal impairment (CrCl ≤50 mL/min).1


  1. ZAVICEFTA. Summary of Product Characteristics 
  2. ZINFORO. Summary of Product Characteristics
  3. Joseph C, et al. Influenza Other Respir Virus 2013;7:105-13
  4. Laudano JB. J Antimicrob Chemother 2011;66:iii11-18
  5. File TM, et al. Clin Infect Dis 2010;51:1395-405
  6. Eckburg P, et al. Infect Dis Clin Pract 2012;20:254-60. 
  7. Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7
  8. ​​​​​​​Riccobene TA, et al. Antimicrob Agents Chemother 2016;60:5849-57
  9. Torres A, et al. Lancet Infect Dis 2018;18:285-95
  10. Torres A, et al. Open Forum Infect Dis 2019;6:ofz149;25
  11. Bonine NG, et al. Am J Med Sci 2018;357:103-10
  12. Raman G, et al. BMC Infect Dis 2015;15:395
  13. Mazuski JE, et al. Clin Infect Dis 2016;62:1380-9;26
  14. Carmeli Y, et al. Lancet Infect Dis 2016;16:661-3
  15. Wagenlehner FM, et al. Clin Infect Dis 2016;63:754-62

PP-ZVA-GBR-1556. May 2022

Want to find out more...

for the treatment of community-acquired pneumonia (CAP) in neonates, infants, children, adolescents and adults2

Visit the Zinforo site

Want to find out more...

for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)

Visit the Zavicefta site
Ask Zavibot a Question

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?